Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

In the News
Greg Scott presents industry update during JPMorgan
>> View video…

>> More News...

Now on Twitter!
 

Twitter ID: ChinaBio

Simcere to Make and Market Flu Drug Zanamivir in China

publication date: May 6, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Simcere Pharmaceutical Group (先声药业) will seek approval from the SFDA to manufacture and sell products containing the flu drug zanamivir. Zanamivir was developed by GlaxoSmithKline, which sells it under the brand name Relenza. Simcere has held a license to produce zanamivir since 2006, the only mainland China biopharma to hold such a license. Zanamivir is one of only two flu drugs that seem to be effective against the H1N1 strain of influenza. More details...

Stock Symbol: (NYSE: SCR) (NYSE: GSK)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
ChinaBio® Events
April 14, 2010
Guangzhou, China

SEED Final Competion and Award Ceremony
April 23, 2010
Shanghai, China
Suzhou, China
June 23-24, 2010
 
Partner Events

China 2010 Pharmaceutical R&D Summit
Shanghai, China
April 5-8, 2010

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners